Exact Sciences Corporation EXAS | NASDAQ
Next Earnings: Jul 29, 2025
Company Overview:
6.4 Year EXAS Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
EXAS Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for EXAS
Based on past 6.4-year performance, here are EXAS growth metrics:
Share price CAGR of -7.51%
Dividend CAGR of +0%
Using EXAS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| EXAS (DRIP) | EXAS - No DRIP | |
|---|---|---|
| Current Price | $54.65 | $54.65 |
| Start Shares | 182.98 | 182.98 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 182.98 | 182.98 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $27.06 | $54.65 |
| Total Dividends | $0 | $0 |
| Final Value | $4,952 | $10,000 |
NOTE: Above numbers are our estimate based on EXAS's Dividend and Price CAGR over past 6.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Exact Sciences Corporation (EXAS) had its IPO on 2001-02-01, and is trader on NASDAQ stock exchange.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS website: https://www.exactsciences.com
